PharmaMar participates in 13th Biennial Meeting of the International Gynecologic Cancer Society (IGCS)

- ***More than 2,500 gynecologic cancer specialists from all over the world attended.***
- ***During the Meeting, PharmaMar held a Satellite Symposium Symposium on Yondelis® (trabectedin) at which leading experts highlighted the importance of Yondelis as a new therapeutic option in patients with platinum-sensitive recurrent ovarian cancer.***
- ***The Company announced the initiation of INOVATYON, a new Phase III clinical trial comparing Yondelis + pegylated liposomal doxorubicin (DLP) towith a platinum-based combination with Yondelis in patients with relapsed ovarian cancer progressing-within 6-12 months after their last platinum dose.***
- ***Participants in the Satellite Symposium also presented data showing the greater progression-free survival and reduced mortality risk of patients with a 6-12 month platinum-free interval when treated with trabectedin (Yondelis) in combination with DLP when compared to DLP alonePLD.***

Madrid, 27 October 2010: The 13th Biennial Meeting of the International Gynecologic Cancer Society (IGCS) was held from 22-26 October in Prague (Czech Republic); more than 2,500 gynecologic cancer specialists from all over the world attended.

International experts highlighted the important role of Yondelis, the first antitumour drug marketed by PharmaMar, S.A. (Grupo Zeltia, ZEL.MC), as a new non-platinum/non-taxane therapeutic option for patients with relapsed ovarian cancer. The Satellite Symposium: **"Trabectedin: Changing paradigms in the treatment of relapsed Ovarian Cancer"**, was moderated by **Dr. Andrés Poveda** (Fundación Instituto Valenciano de Oncología) and participants included **Dr. Ray-Coquard** (Centre Léon Bérard, Lyon, France), **Dr. Antonio González** (M.D. Anderson International, Madrid, Spain), **Prof. Jonathan Ledermann** (UCL Cancer institute, London, UK) and Prof**. Nicoletta Colombo** (University of Milan – Bicocca, Italy).

It was announced that the **INOVATYON** clinical trial has commenced in which Yondelis+pegylated liposomal doxorubicin (PLD) is compared with a combination of platinums in ovarian cancer patients with a platinum-free interval of 6-12 months.

The end point of the new trial is to demonstrate the benefits of extending the platinum-free interval on patients' overall survival.

Changing paradigms in the treatment of relapsed ovarian cancer

The data presented at the conference confirm the efficacy of Yondelis in combination with PLD in platinum-sensitive patients with relapsed ovarian cancer when compared with PLD alone. The results also reveal greater progression-free survival and a 41% reduction in the mortality risk of platinum-sensitive patients with a 6-12 month platinum-free interval.

It was also confirmed that the clinical response according to the RECIST criteria (variations in tumour diameter) was preceded by a favourable decline in CA-125 levels in a large proportion of patients, suggesting the possbility ofusing this variable measurement for assessing tumour progression in future clinical trials.

Moreover, treatment using Yondelis in combination with PLD has a predictable, manageable tolerability profile. Suggest describing safety data

The European Commission approved Yondelis for platinum-sensitive relapsed ovarian cancer (ROC) in September 2009. In 2007, the Commission approved Yondelis for the treatment of advanced soft tissue sarcoma (STS). Numerous clinical trials are currently under way with Yondelis, including a Phase III trial in first-line treatment of STS patients with translocation-associated tumours and in children with Ewing sarcoma, rhabdomyosarcoma and other subtypes of STS.

About PharmaMar

PharmaMar is Grupo Zeltia's biotechnology subsidiary; it is a world leader in discovering, developing and selling marine-based drugs to treat cancer. Yondelis is Spain's first antitumour drug. Yondelis is currently approved for STS in 33 countries outside the EEA, and in 10 of those countries for platinum-sensitive ROC besides Brazil and Canada. Yondelis is approved for STS and platinum-sensitive ROC in all 30 countries of the EEA; in Switzerland it is approved for STS. Phase II clinical trials with Yondelis are also under way on prostate, breast, lung and paediatric cancers. PharmaMar has four other compounds in clinical development: Aplidin®, Irvalec®, Zalypsis® and PM01183. PharmaMar also has a rich pipeline of pre-clinical candidates and a major R&D programme.

About Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech

firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genómica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two profitable companies that are leaders in their respective market segments.

Important note

PharmaMar, which is headquartered in Madrid (Spain), is a subsidiary of Grupo Zeltia (Spanish stock exchange: ZEL), which has been listed on the Spanish Stock Exchange since 1963 and on Spain's Electronic Market since 1998. This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

For more information +34 91 444 4500

This note is also available on the PharmaMar web site: www.pharmamar.com and at Zeltia's web site: www.zeltia.com